Discover the World of Telix Pharmaceuticals' Innovations
Telix Pharmaceuticals Limited (NASDAQ: TLX) invites investors to an insightful webinar featuring its latest advancements in radiotherapeutics within urologic oncology. This engaging event is set to showcase a range of late-stage and next-generation candidates paving the way for new treatments in the field.
Learn from Leading Experts in Urologic Oncology
Join experts who will present valuable insights into their ongoing research and clinical trials, enhancing our understanding of treatments for prostate and kidney cancers. This educational opportunity will feature a combination of presentations and discussions from globally recognized authorities.
Prostate Cancer Focus with TLX591
Neeraj Agarwal, MD, a prominent figure from the Huntsman Cancer Institute, will take center stage to discuss the ProstACT Global Phase 3 trial concerning TLX591 (177Lu rosopatamab tetraxetan). This pivotal study highlights Telix's innovative radio antibody-drug conjugate therapy for prostate cancer, emphasizing the potential benefits it may offer to patients.
Renal Cell Carcinoma Insights with TLX250
Additionally, Eric Jonasch, MD, from MD Anderson Cancer Center, will delve into the STARLITE studies focusing on TLX250 (177Lu girentuximab). These studies explore the effectiveness of combining this radio conjugate with immunotherapy for clear cell renal cell carcinoma, showcasing Telix's commitment to evolving treatments.
Targeted Alpha Therapies with TLX592
Rodney Hicks, MD, an influential professor at the University of Melbourne, will discuss TLX592 (64Cu/225Ac RADmAb) and its role within targeted alpha therapies for treating prostate cancer. Understanding these therapies opens new avenues in safe and effective cancer treatment.
Webinar Event Details
Mark your calendars for this enlightening event taking place at:
EDT: Tuesday, 5:30 PM
AEDT: Wednesday, 8:30 AM
This immersive session will last approximately 1.5 hours and provide updated information on cutting-edge oncology treatments.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company dedicated to the advancement of diagnostic and therapeutic radiopharmaceuticals. Headquartered in Melbourne, Australia, it operates internationally across the United States, Canada, Europe, and Japan. Telix’s portfolio is focused on addressing unmet medical needs in rare diseases and oncology, aiming to bring innovative solutions to market.
Currently, Telix is involved in several clinical trials targeting critical oncology and rare disease areas. With companies like ARTMS and RLS as part of the Telix Group, the collaboration aims to significantly improve patient outcomes.
Stay Connected with Telix
For those looking to stay updated on Telix's progress and industry happenings, visiting their official website and following them on social media platforms proves invaluable. By engaging with their content, investors and interested parties can gain insights into future developments and opportunities to participate in cutting-edge therapies.
Frequently Asked Questions
What is the purpose of the Telix Pharmaceuticals webinar?
This webinar aims to showcase Telix's advancements in urologic oncology and provide insights from industry experts.
Who will present at the Telix Pharmaceuticals webinar?
Leading experts including Neeraj Agarwal, Eric Jonasch, and Rodney Hicks will present their research and insights.
How can I participate in the webinar?
Interested participants can register for the webinar by visiting the Telix Pharmaceuticals official website.
What products are being discussed during the webinar?
The focus will be on radiotherapeutic candidates TLX591, TLX250, and TLX592, highlighting their clinical trials and potential in oncology.
Where is Telix Pharmaceuticals based?
Telix Pharmaceuticals is headquartered in Melbourne, Australia, and has operations globally, aiming to broaden its impact in the field of biopharmaceuticals.
